spacer
home > pmps > autumn 2003 > oral delivery of poorly soluble drugs, part 2: formulation strategies for solid dosage forms and novel delivery systems for controlled release
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Oral Delivery of Poorly Soluble Drugs, Part 2: Formulation Strategies for Solid Dosage Forms and Novel Delivery Systems for Controlled Release

The preferred route of oral administration is limited to those drug molecules that are permeable across the gastric mucosa and are at least sparingly soluble. A large majority of the new chemical entities and many existing drug molecules are poorly soluble, thereby limiting their potential uses and increasing the difficulty of formulating bioavailable drug products. There are numerous methods that may facilitate solubility to further enhance performance of poorly soluble drugs for oral administration - several of the techniques available to formulators aimed at facilitating solubility were generally discussed in Part 1 of this article (1). This review focuses on formulation components and novel controlled release technologies, employed to produce a solid oral dosage form which can increase or enhance in vivo solubility of poorly soluble molecules.

While this review focuses on solid oral systems, a number of other systems are available for the oral delivery of low solubility drugs, including lipid-based soft-gel systems and self-emulsifying formulations comprising a lipid component and one or more surfactants. Such lipid-based systems are effective in their pursuit of solubilising low solubility drugs, but often require unique production processes and may be difficult to incorporate into controlled release formulations. Osmotic pumps also offer a highly effective method of delivery and are capable of linear release for even nearly insoluble drugs, but are limited in formation flexibility and are complex to manufacture. Solid dosage forms remain the most economic method of delivering any compound precisely due to the large range of technologies available and their familiarity to both the formulator and the manufacturer.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michael Hite, Lead Research Associate, Stephen Turner, Director of Product Development, and Cathy Federici, Research Associate, members of the Research and Product Development Group at SCOLR® Inc

Michael Hite, Lead Research Associate, Stephen Turner, Director of Product Development and Cathy Federici, Research Associate are all members of the Research and Product Development group at SCOLR® Inc, a drug delivery company specialising in the development and application of novel oral drug delivery systems. Michael is a graduate of Amherst College, Stephen is a graduate of Western Washington University and Cathy a graduate of Swarthmore College. They joined SCOLR® in 2000, 1999 and 2001 respectively.



spacer
Michael Hite
spacer
spacer
spacer
Stephen Turner
spacer
spacer
spacer
Cathy Federici
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement